Nammi Therapeutics develops platforms and products designed to selectively activate anti-tumor immunity in the tumor microenvironment while reducing systemic immune activation to improve safety and enable combination regimens. The company has developed a Masked Immunocytokine (MIC) platform and a nanoparticle platform called Nammisome to deliver Immune Modulating Prodrugs (IMPs). Its lead program, QXL138AM, is a MIC comprised of a masked interferon alpha fused to an antibody targeting CD138; tumor-surface proteases remove the mask to activate IFNa locally. Preclinical data show significant anti-tumor efficacy across more than 10 tumor types, including complete regressions in multiple myeloma at doses as low as 0.1 mg/kg, and Nammi has secured FDA Orphan Drug Designation in multiple myeloma. The company is led by President and CEO David Stover, Ph.D., and is based in Los Angeles, CA. The financing activity described in the article occurred prior to the planned start of a first-in-human Phase 1 study of QXL138AM. Nammi Therapeutics develops a nanoparticle drug-delivery platform (Namm-1) that co-delivers the chemotherapy doxorubicin and the small-molecule immunotherapy 1-MT into tumors to kill cancer cells and stimulate an immune response. The technology originated from UCLA research by Andre Nel and Huan Meng and is designed for cancers including breast, ovarian and Kaposi’s sarcoma. The company claims its nanoparticle can ferry a combined chemo‑immunotherapy payload with fewer side effects and potentially lower cost than many precision therapies. Nammi leased lab space at Magnify (the CNSI bioscience incubator at UCLA), currently has three employees, and is hiring additional researchers. Financially, Nammi completed an $8.2M seed round from 17 investors and is pursuing a roughly $20M Series A; it is also seeking a pharmaceutical partner to help fund development and commercialization. The firm expects to launch a clinical trial (for a breast‑cancer indication) by early 2020 and is led by CEO David Stover with Donald Rice as board chair.

Total raised

$38M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2024